Professor Rachael Morton, a leader in health economics at the NHMRC Clinical Trials Centre, the University of Sydney, and a key figure in ACEMID, has been awarded a MRFF grant to explore digital versus face-to-face services for skin cancer diagnosis.
Precision medicine driven diagnostic health technologies are rapidly evolving, including innovative technologies like 3D total body imaging, digital dermoscopy, and artificial intelligence (AI) driven lesion diagnosis.
The project’s focus is to explore the dynamic between digital versus traditional face-to-face services for skin cancer diagnosis.
Professor Morton and her team aim to comprehensively identify the costs, benefits, and preferences of patients, clinicians, and the wider community regarding digital versus face-to-face skin cancer diagnostic services. The heart of the project lies in the development of a health economic model, designed to compare the relative costs and benefits of continuous monitoring using digital services (3D total body imaging, digital dermoscopy, and AI-driven lesion diagnosis) against face-to-face services for skin cancer diagnosis. This comparison will be enacted across various healthcare settings, shedding light on the practicality and efficiency of integrating this technology into standard clinical care scenarios.
This project will commence in December 2023 and run over four years.
This venture is a collaborative effort that brings together researchers and consumer advocates from the University of Sydney, University of Queensland, Monash University, Melanoma & Skin Cancer Advocacy Network and Medical University Vienna.
